Abstract：
Pre-exposure prophylaxis (PrEP) availability through the Pharmaceutical Benefits Scheme provides real potential for the elimination of HIV transmission in Australia, as evidenced by a rapid decline in HIV incidence among gay and bisexual men (GBM). However, HIV elimination will not be possible without also extending PrEP to other populations, including cisgender women. We conducted a scoping review to examine the extent to which PrEP access for cisgender women has been considered in Australia. A comprehensive search across five databases, grey literature, and hand search of references was conducted. A single reviewer conducted title and abstract screening and two reviewers completed full-text screening and data extraction. Nineteen documents were included in the final review and included both peer-reviewed journal articles and guidelines and strategies. Focused discussion of cisgender women\'s use of PrEP was largely missing from the literature and, although their use of PrEP is supported in some relevant guidelines, little has been done to actively develop strategies to inform cisgender women about PrEP as a precursor to prescribing for HIV prevention. Healthcare providers\' narrow view of PrEP as being the domain of GBM further limits cisgender women\'s potential access. If HIV elimination in Australia is to be a reality, we need to develop mechanisms to specifically engage with cisgender women about PrEP.
摘要：
通过药物福利计划提供的暴露前预防（PrEP）为消除澳大利亚的艾滋病毒传播提供了真正的潜力。这可以从男同性恋者和双性恋者（GBM）中艾滋病毒发病率的快速下降中得到证明。然而,如果不将PrEP扩展到其他人群，就不可能消除艾滋病毒。包括顺式女性。我们进行了范围审查，以检查在澳大利亚考虑对顺性女性进行PrEP的程度。对五个数据库进行全面搜索，灰色文学，并对参考文献进行了手工搜索。一名审阅者进行了标题和摘要筛选，两名审阅者完成了全文筛选和数据提取。最终审查包括19份文件，其中包括同行评审的期刊文章以及指南和策略。文献中很大程度上缺少对顺性女性使用PrEP的重点讨论，尽管一些相关指南支持他们使用PrEP，在积极制定战略以告知顺性别妇女PrEP作为预防艾滋病毒处方的先兆方面，几乎没有采取任何措施。医疗保健提供者将PrEP视为GBM领域的狭隘观点进一步限制了顺性别女性的潜在获取途径。如果要在澳大利亚消除艾滋病毒成为现实，我们需要建立专门与顺性别女性进行PrEP的机制。
